{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"anti-veltuzumab antibodies"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"anti-milatuzumab antibodies"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Patients will be monitored for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA).","groups":[{"description":"Phase I: patients receive Veltuzumab IV weekly on day 1 for 4 doses and Milatuzumab weekly for total of 4 doses during induction therapy. Induction therapy during week 1 patients receive Veltuzumab alone on day 1 and Milatuzumab alone on day 2 to prevent overlapping infusion reactions. Week 2 Veltuzumab on day 1 and Milatuzumab on day 4.\n\nPhase II: patients receive Veltuzumab IV weekly for 4 doses and Milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy.","id":"OG000","title":"All Patients From Phase I and Phase II"}],"paramType":"NUMBER","populationDescription":"HAHA titres were assayed for patients in Phase I and Phase II","reportingStatus":"POSTED","timeFrame":"up to 36 weeks","title":"Monitor Human Anti-veltuzumab Antibodies and Human Anti-milatuzumab (HAHA)","type":"SECONDARY","unitOfMeasure":"patients"}